Investing.com --Bausch + Lomb Corp (NYSE:BLCO) shares tumbled more than 12% on Wednesday in New York Stock Exchange after report that Blackstone (NYSE:BX) could back away from a joint bid to acquire the eyecare company, raising doubts about one of the largest healthcare buyouts of the year.
The private equity giant had teamed up with investor TPG in October to explore a bid for Bausch + Lomb . However, Financial Times reported citing sources that Blackstone has grown wary of the seller’s high price expectations.
Citi downgraded Bausch + Lomb to “neutral” from “buy” in a note on Wednesday, slashing its price target to $22 from $24.
The auction process for Bausch + Lomb, known for its contact lenses, dry eye treatments, and surgical ophthalmology devices, began earlier this year as its debt-laden parent, Bausch Health, seeks to reduce its liabilities.
Related Articles
Bausch + Lomb down after report that Blackstone could back away from takeover bid
Albertsons demands billions from rival Kroger after terminating merger bid
Global shares, US dollar rise as inflation data reinforces Fed hopes
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。